Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues

(2015) Gareth W. Jones et al.   IMMUNOLOGY

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Memory programming in CD8+ T-cell differentiation is intrinsic and is not determined by CD4 help

(2015) Juhyun Kim et al.   Nature Communications

Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity

(2015) Claire Germain et al.   Frontiers in Immunology

Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer

(2014) Claire Germain et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Tertiary lymphoid structures in cancer and beyond

(2014) Marie-Caroline Dieu-Nosjean et al.   TRENDS IN IMMUNOLOGY

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

Dual roles for immune metagenes in breast cancer prognosis and therapy prediction

(2014) Angela Alistar et al.   Genome Medicine

Meta-analysis and metagenes

(2014) Davide Bedognetti et al.   OncoImmunology

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

(2013) Helen Angell et al.   CURRENT OPINION IN IMMUNOLOGY

Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer

(2013) Gabriela Bindea et al.   IMMUNITY

RNA recognition by human TLR8 can lead to autoimmune inflammation

(2013) Cristiana Guiducci et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Strength of PD-1 signaling differentially affects T-cell effector functions

(2013) F. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

INTERFEROME v2.0: an updated database of annotated interferon-regulated genes

(2012) Irina Rusinova et al.   NUCLEIC ACIDS RESEARCH

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

(2011) Y. H. Kim et al.   BLOOD

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors

(2011) F. Aranda et al.   CANCER RESEARCH

Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma

(2011) G. R. Weiss et al.   CLINICAL CANCER RESEARCH

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9

(2010) Cristiana Guiducci et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CXCL13 Blockade Disrupts B Lymphocyte Organization in Tertiary Lymphoid Structures without Altering B Cell Receptor Bias or Preventing Diabetes in Nonobese Diabetic Mice

(2010) R. A. Henry et al.   JOURNAL OF IMMUNOLOGY

B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice

(2010) D. J. DiLillo et al.   JOURNAL OF IMMUNOLOGY

Spontaneous Regression of Highly Immunogenic Molluscum contagiosum Virus (MCV)-Induced Skin Lesions Is Associated with Plasmacytoid Dendritic Cells and IFN-DC Infiltration

(2010) William Vermi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

(2010) Massimo Ammirante et al.   NATURE

Memories that last forever: strategies for optimizing vaccine T-cell memory

(2009) J. D. Ahlers et al.   BLOOD

Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells

(2008) Naoko Imai et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides

(2008) Tahamtan Ahmadi et al.   IMMUNOLOGY

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA